Limited Offer
New Developments in Myeloma, An Issue of Hematology/Oncology Clinics of North America
- 1st Edition, Volume 38-2 - March 1, 2024
- Editor: Peter Leif Bergsagel
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 1 3 0 7 7 - 9
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 3 0 7 8 - 6
In this issue of Hematology/Oncology Clinics, guest editor Dr. P. Leif Bergsagel brings his considerable expertise to the topic of New Developments in Myeloma. With the advent of… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteIn this issue of Hematology/Oncology Clinics, guest editor Dr. P. Leif Bergsagel brings his considerable expertise to the topic of New Developments in Myeloma. With the advent of next generation sequencing and immune profiling technologies, marked advances have been made recently in the understanding of the molecular and immune pathogenesis of multiple myeloma. Yet even with these advances, there is a continual search for new therapeutic approaches. In this issue, top experts discuss a full range of clinically relevant topics in this complex and fast-changing field.
- Contains 16 relevant, practice-oriented topics including molecular pathogenesis of multiple myeloma; monoclonal antibodies in the treatment of multiple myeloma; CAR-T cells in the treatment of multiple myeloma; management of newly diagnosed multiple myeloma today, and in the future; approach to high-risk multiple myeloma; new therapies on the horizon for relapsed refractory multiple myeloma; and more.
- Provides in-depth clinical reviews on new developments in myeloma, offering actionable insights for clinical practice.
- Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
Hematology, oncology
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Forthcoming Issues
- Preface
- Dedication
- Molecular Pathogenesis of Multiple Myeloma: Clinical Implications
- Key points
- Introduction
- Multiple myeloma is preceded by an asymptomatic monoclonal gammopathy
- Immunoglobulin heavy chain gene translocations and hyperdiploidy are primary genetic events
- Secondary genetic events cause the progression to symptomatic multiple myeloma
- Impact of intratumor subclonal heterogeneity on disease progression and drug resistance
- Summary
- Clinics care points
- Immune-Pathogenesis of Myeloma
- Key points
- Introduction
- Immune recognition of premalignancy
- Role of spatial architecture in multiple myeloma immunopathogenesis
- Role of chronic B cell activation
- Understanding premonoclonal gammopathy of undetermined significance
- Diverse mechanisms underlie immune paresis in multiple myeloma
- Nonimmunologic contributions of immune cells in multiple myeloma
- Summary and future directions
- Clinics care points
- Smoldering Multiple Myeloma: Observation Versus Control Versus Cure
- Key points
- Introduction
- Diagnostic criteria and clinical features
- Risk stratification
- Approach to treatment
- Future directions
- Clinics care points
- Cereblon-Targeting Ligase Degraders in Myeloma: Mechanisms of Action and Resistance
- Key points
- Introduction
- Mechanisms of action
- Mechanisms of resistance to immunomodulatory imide drugs and cereblon E3 ligase modulators
- CRBN-independent resistance mechanisms
- Summary
- Clinics care points
- Proteasome Inhibitors in Multiple Myeloma: Biological Insights on Mechanisms of Action or Resistance Informed by Functional Genomics
- Key points
- Introduction
- The proteasome complex and its inhibitors
- The evolving conceptual framework on molecular mechanisms mediating anti-multiple myeloma effects of proteasome inhibition
- Insights from functional genomics of multiple myeloma on the mediators of proteasome inhibitor activity
- Current state and future perspectives on mechanisms of resistance to proteasome inhibitors
- Future perspectives on the basic and translational studies of proteasome inhibition
- Monoclonal Antibodies in the Treatment of Multiple Myeloma
- Key points
- Introduction
- CD38-targeting antibodies
- Summary
- Clinics care points
- Bispecific Antibodies in the Treatment of Multiple Myeloma
- Key points
- Introduction
- Potential bispecific antibody targets and mechanisms of action
- Selected clinical data of bispecific antibodies in relapsed/refractory multiple myeloma
- Potential resistance mechanisms
- Summary and outlook
- Clinics care points
- Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma
- Key points
- Introduction
- History of chimeric antigen receptor T cell therapy in myeloma
- Idecabtagene vicleucel: KarMMa trial and other data in late line multiple myeloma
- Ciltacabtagene autoleucel: CARTITUDE-1 and other data in late line multiple myeloma
- Chimeric antigen receptor T cells in earlier lines and role of maintenance
- Other B cell maturation antigen-directed chimeric antigen receptor T cells in clinical development
- Toxicities of chimeric antigen receptor T cell therapies
- Non-B cell maturation antigen-directed chimeric antigen receptor T cells for myeloma
- Ongoing challenges and potential solutions
- Summary
- Clinics care points
- Is There Still a Role for Stem Cell Transplantation in Multiple Myeloma?
- Key points
- Introduction
- Summary
- Clinics care points
- Role of Consolidation and Maintenance
- Key points
- Introduction
- Discussion
- Summary
- Summary and future directions
- Clinics care points
- Management of Newly Diagnosed Multiple Myeloma Today, and in the Future
- Key points
- Introduction
- Transplant-eligible patients
- Transplant-ineligible patients
- Future directions
- Summary
- Clinics care points
- Impact of Clonal Heterogeneity in Multiple Myeloma
- Key points
- Introduction
- Initiating and progression events and their impact on outcome
- Spatial clonal heterogeneity
- Clonal heterogeneity and the bone marrow microenvironment
- Clonal heterogeneity and treatment resistance
- Overcoming clonal heterogeneity
- Summary
- Clinics care points
- Measurable Residual Disease and Decision-Making in Multiple Myeloma
- Key points
- Introduction
- A primer on measurable residual disease in myeloma
- Measurable residual disease as a prognostic tool
- Measurable residual disease result interpretation
- Measurable residual disease as a surrogate endpoint
- Measurable residual disease to guide decision-making
- “Hot takes” and burning questions
- Clinics care points
- Approach to High-Risk Multiple Myeloma
- Key points
- Introduction
- The clinical problem associated with high-risk myeloma
- Conceptually what is high-risk myeloma, and how should it be addressed therapeutically?
- Cytogenetic markers of high-risk disease
- Prognostic scoring systems
- Biologic, genetic, and epigenetic features of high risk
- The high-risk microenvironment
- Therapeutic considerations
- Mechanisms of relapse
- Consensus definitions
- Summary
- Clinics care points
- New Therapies on the Horizon for Relapsed Refractory Multiple Myeloma
- Key points
- Introduction
- Discussion
- Summary
- Clinics care points
- Immunocompetent Mouse Models of Multiple Myeloma: Therapeutic Implications
- Key points
- Introduction
- Discussion
- Summary
- Clinics care points
- No. of pages: 240
- Language: English
- Edition: 1
- Volume: 38-2
- Published: March 1, 2024
- Imprint: Elsevier
- Hardback ISBN: 9780443130779
- eBook ISBN: 9780443130786
PB
Peter Leif Bergsagel
Affiliations and expertise
Novel Therapeutics for Cancer Research, Director, Mayo Clinic SPORE in Multiple Myeloma, Co-Director, Hematologic Malignancies Program, Mayo Clinic Cancer Center, Consultant, Division of Hematology/Oncology, Professor of Medicine, Mayo Clinic College of Medicine